Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
German unemployment rate falls to 6.4%, but 3 million still jobless - 2December's overlooked meteor shower peaks next week — will the Ursids surprise us?
- 3Beyond the habitable zone: Exoplanet atmospheres are the next clue to finding life on planets orbiting distant stars
- 4A photographer's journey to capture a blood moon rising over the South China Sea. 'It was an incredible moment'
- 5Commonsense Ways to work on Your Funds with a Restricted Pay
- 2025 Was Another Exceptionally Hot Year
- Instructions to Shield Your Gold Speculation from Possible Dangers: Fundamental Protections
- Cyber Monday 2025 streaming deal: Get $42 off six months of Apple TV
- She loves to give experiences. He goes for sentimental gifts. They ask an expert: What is the perfect holiday present?
- Moon-bound Artemis II astronauts enjoy a relaxed day in space
- The Difficulties of Getting a Green Card in the US
- Interstellar comet 3I/ATLAS to pass closest to Earth on Friday
- CNN Crew Detained and Journalist Put in Chokehold in IDF Run-In: ‘We’re Journalists. What Are You Doing?!’
- Fossils unearthed in Morocco are first from little-understood period of human evolution
